Arbutus Biopharma Corp (ABUS)

2.65
-0.16(-5.69%)
After Hours
2.65
0.00(0.00%)
- Real-time Data
  • Volume:
    1,291,631
  • Bid/Ask:
    2.65/2.69
  • Day's Range:
    2.65 - 2.85

ABUS Overview

Prev. Close
2.81
Day's Range
2.65 - 2.85
Revenue
7.53M
Open
2.84
52 wk Range
1.24 - 9.02
EPS
-0.96
Volume
1,291,631
Market Cap
255.43M
Dividend (Yield)
N/A (N/A)
Average Vol. (3m)
1,745,792
P/E Ratio
-
Beta
2.91
1-Year Change
108.15%
Shares Outstanding
96,387,749
Next Earnings Date
Aug 05, 2021
What is your sentiment on Arbutus Biopharma Corp?
or
Market is currently closed. Voting is open during market hours.

Arbutus Biopharma Corp News

Arbutus Biopharma Corp Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell

Arbutus Biopharma Corp Company Profile

Arbutus Biopharma Corp Company Profile

Employees
78

Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing cure for people with chronic hepatitis B virus (HBV) infection. Its product pipeline is focused on finding curative combination regimen for chronic HBV infection, with the objective of developing a suite of products that intervene at different points in the viral life cycle and reactivate the host immune system. It is developing a product pipeline consisting of multiple drug candidates with complementary mechanisms of action. The Company’s HBV product pipeline includes ribonucleic acid (RNA) interference (RNAi) therapeutics, oral capsid inhibitors, oral compounds that inhibit programmed death-ligand one (PDL1) and oral HBV RNA destabilizers. Its subsidiaries include Arbutus Inc and Arbutus Biopharma US Holdings, Inc.

Read More
  • trash
    0
    • Next week ABUS is going to be skyrocket.
      0
      • why next week? bc of Financials?
        0
      • yeah, why? I think this could get to 15$ at summer. but not next weej
        0
      • can you point the skyrocket up? it's pointed down
        0
    • Good day today, more to follow!
      0
      • With the strong biotech volatility going on, I still wonder why ABUS is not yet above $10. Highly interesting pipeline with HBV infection drug products candidates, RNA technology and sooner or later we should know if they are receiving big stake on future's Modernas revenue (patent issue).
        0
        • Buy today - this is going up big on Monday
          0
          • It is up 7% now. Is there anyone who knows the reason?
            0
            • No special reason, but it has a stable product for long term
              0
            • Carlos Andres I am waiting for long time wit loss but it doesn't move up. I hope this time it does. I am searching for news about the company but cannot find anything.
              0
          • Moderna Inc (O:MRNA) should  pay ABUS  coronavirus vaccine patent. hope the price up
            0
            • do you know when it is due?
              0
            • Link?? Source??
              0
          • All financials seem to be solid and seems ready to rocket 🚀 ABUS has LNP delivery for RNA, 123 million in bank, partner with ALNY, Gristone, Roviant, Genevant. HBV going into 2nd phase. Affliiated with BNTX. Abus should be $30.00 min.
            0
            • why is this bad scene then? I guess the volume is very very low. do you jnow when its financials? perhaps it may save us
              0
          • $ABUS will be a rocket ride.
            0
            • when my friend? for a long time it is very slow and generally disappointing
              1
          • Up like a rocket soon
            0
            • 7 very soon
              0
              • also investing recommends strong buy. does it worth considering?
                0
                • It is very cheap for now. what is the prediction for the long term?
                  0
                  • good time to buy with MRNA news and ride MRNA
                    0
                    • good time to buy with MRNA good news
                      0
                      • a U.S. patent owned by Arbutus Biopharma Corp (O:ABUS) that poses a potential obstacle to Moderna's efforts to develop next-generation vaccines. so it wlll be up above 4 after MRNA good news
                        0
                        • Will go above 4 dollars? Are their products reliable enough?
                          0
                          • strong
                            0
                            • big vol in so solid
                              0
                              • yes!
                                0
                                • Strong now. Good moment to buy long
                                  0
                                  • Not selling under 10
                                    0
                                    • Any good news?
                                      0
                                  • https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-ab-729-90-mg-single-dose-week-12-data-chronic
                                    0
                                    • ohoo Arbutus $
                                      0
                                      • This stock is probbaly dead, right??? More than a week without a single comment? I am probably the only one waiting to buy it.
                                        1
                                        • I'm waiting and I guess the stock will wake up
                                          0
                                        • Put your money to better use
                                          0
                                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.